Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- HEMO.LSE
- Price
- 168.50
- Stock movement down
- -0.25 (-0.15%)
- Company name
- Hemogenyx Pharmaceuticals PLC
- Exchange
- (LSE ,
- Currency
- GBX )
- Sector
- Healthcare >Biotechnology
- Market cap
- 590.51M
- Ent value
- 591.97M
- Price/Sales
- -
- Price/Book
- 195.31
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 7.55%
- 1 year return
- -73.67%
- 3 year return
- -35.23%
- 5 year return
- -21.35%
- 10 year return
- -
Last updated: 2025-04-12
DIVIDENDS
HEMO.LSE does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 195.31 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 3.50M |
| EPS (TTM) | - |
| FCF per share (TTM) | -0.00 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -647.46K |
| Operating income (TTM) | -4.49K |
| Net income (TTM) | -5.18K |
| EPS (TTM) | - |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 1.64M |
| Net receivables | 827.87K |
| Total current assets | 2.47M |
| Goodwill | 0.00 |
| Intangible assets | 472.50K |
| Property, plant and equipment | 0.00 |
| Total assets | 6.12M |
| Accounts payable | 308.66K |
| Short/Current long term debt | 2.78M |
| Total current liabilities | 564.26K |
| Total liabilities | 3.09M |
| Shareholder's equity | 3.02M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -5.07K |
| Capital expenditures (TTM) | 106.00 |
| Free cash flow (TTM) | -2.80M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -0.17% |
| Return on Assets | -0.08% |
| Return on Invested Capital | -0.16% |
| Cash Return on Invested Capital | -85.32% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 165.50 |
| Daily high | 173.85 |
| Daily low | 165.50 |
| Daily Volume | 39K |
| All-time high | 5760.00 |
| 1y analyst estimate | - |
| Beta | 3.26 |
| EPS (TTM) | - |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 22 Apr 2025 |
Downside potential
Loading...
Downside potential data
| HEMO.LSE | S&P500 | |
| Current price drop from All-time high | -97.07% | -12.89% |
| Highest price drop | -97.10% | -56.47% |
| Date of highest drop | 9 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -68.95% | -11.07% |
| Avg time to new high | 121 days | 12 days |
| Max time to new high | 1167 days | 1805 days |
COMPANY DETAILS
Marketcap
590.51M
Marketcap category
Small-cap
Description
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood cancer. The company's lead product candidate is the HEMO-CAR-T therapy for the treatment and potential cure for relapsed and/or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat COVID-19 virus, as well as to treat brain cancers and/or certain neurodegenerative diseases; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific antibodies; and cell therapy products for bone marrow/hematopoietic stem cell transplantation. Hemogenyx Pharmaceuticals Plc was incorporated in 2013 and is headquartered in London, the United Kingdom.
Employees
17
Website
Investor relations
-
SEC filings
CEO
Country
UK
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found